Diadema Partners LP Replimune Group, Inc. Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 32,483 shares of REPL stock, worth $296,569. This represents 0.09% of its overall portfolio holdings.
Number of Shares
32,483
Previous 74,530
56.42%
Holding current value
$296,569
Previous $727 Million
58.47%
% of portfolio
0.09%
Previous 0.19%
Shares
3 transactions
Others Institutions Holding REPL
# of Institutions
194Shares Held
80.8MCall Options Held
2.02MPut Options Held
2.86M-
Baker Bros. Advisors LP New York, NY11MShares$101 Million1.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$98.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$43 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.66MShares$42.6 Million5.27% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.91MShares$35.7 Million9.84% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $450M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...